EE349 Cost-Effectiveness of First-Line Treatment With Pembrolizumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer (CRC) in the United States Based on 5-Year Follow-up Data
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.647
https://www.valueinhealthjournal.com/article/S1098-3015(24)00762-9/fulltext
Title :
EE349 Cost-Effectiveness of First-Line Treatment With Pembrolizumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer (CRC) in the United States Based on 5-Year Follow-up Data
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00762-9&doi=10.1016/j.jval.2024.03.647
First page :
Section Title :
Open access? :
No
Section Order :
10123